Spinal Muscular Atrophy| A Pipeline Analysis Report 2018| Technavio

LONDON--()--Technavio has announced their latest pipeline analysis report on the spinal muscular atrophy market. The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat spinal muscular atrophy.

This report by Technavio presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the future.

This report is available at a USD 1,000 discount for a limited time only: View market snapshot before purchasing

Spinal muscular atrophy: Market overview

Spinal Muscular Atrophy (SMA) is a genetic disorder that results in the weakening of the muscles and affects muscle movement. It is common in infants, and it progresses with time. Infants with SMA have a breakdown of nerve cells in the brain and the spinal cord, due to which the brain stops sending control signals that control the muscle movement to the spinal cord. The muscles shrink and become weak, making it tough for the patients to control the head movement, sit without any external support and walk. People with a family history of SMA are at higher risks of developing the disease than the ones with no family history of SMA.

According to a senior market research analyst at Technavio, “As per the data represented by SMA Foundation, the incidence of SMA across all genders, races, and ethnic backgrounds is estimated to be 1 in every 10,000 children born. On the gender front, the probability of an infant developing SMA is almost equal in males and females. With the rising incidences of the disease, the drug development for spinal muscular atrophy is expected to rise during the next few years.”

Spinal muscular atrophy: Segmentation analysis

This pipeline analysis report segments the spinal muscular atrophy market based on therapies employed (monotherapy), RoA (oral, intravenous, and intrathecal), therapeutic modality (small molecule, gene, biological, oligonucleotide and cell), targets (SMN2, SMN1, acetylcholine receptor, 4-aminobutyrate transaminase, myostatin, SMN, and troponin-tropomyosin complex), MoA (SMN2 protein modulator, gene therapy, acetylcholine receptor modulator, cell replacement, 4-aminobutyrate transaminase inhibitor, myostatin activation inhibitor, SMN protein stabilizer, and troponin-tropomyosin complex stimulant ), geographical segmentation (Italy, France, Germany, Japan, US and Belgium) and recruitment status (active, not recruiting, not yet recruiting, and recruiting). It provides an in-depth analysis of the prominent factors influencing the market, including drivers, opportunities, trends, and industry-specific challenges.

Based on therapeutic modality, more than 45% of the molecules that are being investigated for the treatment of spinal muscular atrophy are small molecule.

Looking for more information on this market? Request a free sample report

Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.

Some of the key topics covered in the report include:

Scope of the Report

Regulatory Framework

Drug Development Landscape

  • Drugs under development
  • Indications coverage

Drug Development Strategies

  • Therapies employed
  • RoA
  • Therapeutic modality
  • Geographical coverage

Recruitment Strategies

  • Recruitment status
  • Gender
  • Age

Key Companies

  • Type of players
  • Company overview

Discontinued or Dormant Molecules

About Technavio

Technavio is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.

With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.

If you are interested in more information, please contact our media team at media@technavio.com.


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200

Release Summary

Technavio has published a new report on the drug development pipeline for spinal muscular atrophy, including a detailed study of the pipeline molecule


Technavio Research
Jesse Maida
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200